Evidence has accumulated to show that mucosal healing can alter the course of Crohn's disease. New results from the EXTEND trial clearly demonstrate that adalimumab is able to induce and maintain mucosal healing in Crohn's disease and has the potential for disease modification.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fiorino, G. et al. Adalimumab in Crohn's disease: tips and tricks after 5 years of clinical experience. Curr. Med. Chem. 18, 1230–1238 (2011).
Peyrin-Biroulet, L. et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J. Crohns Colitis 5, 477–483 (2011).
Rutgeerts, P. et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2012.01.035.
Pineton de Chambrun, G., Peyrin-Biroulet, L., Lémann, M. & Colombel, J. F. Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol. 7, 15–29 (2010).
Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383–1395 (2010).
Colombel, J. F. et al. S1045 endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: week 10 and 54 results of the MUSIC trial. Gastroenterology 138 (Suppl. 1), S166 (2010).
Peyrin-Biroulet, L. et al. Development of the Paris definition of early Crohn's disease for disease. Modification trials: results of an International Consensus. Am. J. Gastroenterol. (in press).
D'Haens, G. et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm. Bowel Dis. http://dx.doi.org/10.1002/ibd.22917.
Fiorino, G., Bonifacio, C., Malesci, A., Balzarini, L. & Danese, S. MRI in Crohn's disease—current and future clinical applications. Nat. Rev. Gastroenterol. Hepatol. 9, 23–31 (2011).
Pariente, B. et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm. Bowel Dis. 17, 1415–1422 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S. Danese declares that he has acted as a consultant for Abbott, AstraZeneca, CosmoPher, Novo Nordisk, Schering–Plough and Takeda Millenium, and has been a member of a speakers bureau for Ferring Pharmaceuticals, Merck, UCB Pharma and Vifor Pharma.
L. Peyrin-Biroulet declares that he has acted as a consultant and been a member of a speakers bureau for Abbott and Merck.
Rights and permissions
About this article
Cite this article
Danese, S., Peyrin-Biroulet, L. Mucosal healing—EXTENDing our knowledge in Crohn's disease. Nat Rev Gastroenterol Hepatol 9, 309–311 (2012). https://doi.org/10.1038/nrgastro.2012.77
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2012.77
This article is cited by
-
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
Nature Reviews Gastroenterology & Hepatology (2013)
